EUR 76.5
(0.0%)
Year | Net Income | Net Income Growth |
---|---|---|
2023 | 55.56 Million EUR | 15.76% |
2022 | 47.99 Million EUR | -23.65% |
2021 | 62.86 Million EUR | 227.04% |
2020 | 19.22 Million EUR | -32.77% |
2019 | 28.58 Million EUR | -21.15% |
2018 | 36.25 Million EUR | 4.1% |
2017 | 34.83 Million EUR | 25.17% |
2016 | 27.82 Million EUR | 15.2% |
2015 | 24.15 Million EUR | -6.25% |
2014 | 25.76 Million EUR | 9.27% |
2013 | 23.58 Million EUR | 4.48% |
2012 | 22.56 Million EUR | -0.56% |
2011 | 22.69 Million EUR | 1.98% |
2010 | 22.25 Million EUR | 22.23% |
2009 | 18.2 Million EUR | -1.92% |
2008 | 18.56 Million EUR | -0.42% |
2007 | 18.64 Million EUR | 17.81% |
2006 | 15.82 Million EUR | 27.2% |
2005 | 12.44 Million EUR | 0.0% |
Year | Net Income | Net Income Growth |
---|---|---|
2024 Q2 | 23.8 Million EUR | 0.0% |
2023 Q2 | 32.22 Million EUR | 0.0% |
2023 Q4 | 23.33 Million EUR | 0.0% |
2023 FY | 55.56 Million EUR | 15.76% |
2022 Q4 | 26.59 Million EUR | 0.0% |
2022 FY | 47.99 Million EUR | -23.65% |
2022 Q2 | 21.4 Million EUR | 0.0% |
2021 FY | 62.86 Million EUR | 227.04% |
2021 Q2 | 36.19 Million EUR | 0.0% |
2021 Q4 | 26.66 Million EUR | 0.0% |
2020 Q2 | 15.05 Million EUR | 0.0% |
2020 Q4 | 4.17 Million EUR | 0.0% |
2020 FY | 19.22 Million EUR | -32.77% |
2019 Q2 | 12.99 Million EUR | 0.0% |
2019 FY | 28.58 Million EUR | -21.15% |
2019 Q4 | 15.59 Million EUR | 0.0% |
2018 Q2 | 15.8 Million EUR | 0.0% |
2018 FY | 36.25 Million EUR | 4.1% |
2018 Q4 | 20.45 Million EUR | 0.0% |
2017 Q4 | 20.45 Million EUR | 0.0% |
2017 Q2 | 14.37 Million EUR | 0.0% |
2017 FY | 34.83 Million EUR | 25.17% |
2016 Q4 | 14.32 Million EUR | 0.0% |
2016 Q2 | 13.5 Million EUR | 0.0% |
2016 FY | 27.82 Million EUR | 15.2% |
2015 FY | 24.15 Million EUR | -6.25% |
2015 Q4 | 11.75 Million EUR | 0.0% |
2015 Q2 | 12.4 Million EUR | 0.0% |
2014 Q4 | 15.6 Million EUR | 0.0% |
2014 Q2 | 10.15 Million EUR | 0.0% |
2014 FY | 25.76 Million EUR | 9.27% |
2013 FY | 23.58 Million EUR | 4.48% |
2013 Q2 | 9.94 Million EUR | 0.0% |
2013 Q4 | 13.63 Million EUR | 0.0% |
2012 FY | 22.56 Million EUR | -0.56% |
2012 Q2 | 5.64 Million EUR | 0.0% |
2012 Q4 | 5.89 Million EUR | 4.48% |
2012 Q3 | 5.64 Million EUR | 0.0% |
2012 Q1 | 5.64 Million EUR | 0.0% |
2011 Q2 | 5.67 Million EUR | 0.0% |
2011 Q1 | 5.67 Million EUR | 0.0% |
2011 Q3 | 5.67 Million EUR | 0.0% |
2011 Q4 | 5.64 Million EUR | -0.56% |
2011 FY | 22.69 Million EUR | 1.98% |
2010 Q2 | 5.56 Million EUR | 0.0% |
2010 Q3 | 5.56 Million EUR | 0.0% |
2010 Q4 | 5.67 Million EUR | 1.98% |
2010 FY | 22.25 Million EUR | 22.23% |
2010 Q1 | 5.56 Million EUR | 0.0% |
2009 FY | 18.2 Million EUR | -1.92% |
2009 Q1 | 4.55 Million EUR | 0.0% |
2009 Q4 | 5.56 Million EUR | 22.23% |
2009 Q3 | 4.55 Million EUR | 0.0% |
2009 Q2 | 4.55 Million EUR | 0.0% |
2008 Q1 | 4.64 Million EUR | 0.0% |
2008 FY | 18.56 Million EUR | -0.42% |
2008 Q4 | 4.55 Million EUR | -1.92% |
2008 Q3 | 4.64 Million EUR | 0.0% |
2008 Q2 | 4.64 Million EUR | 0.0% |
2007 Q2 | 4.66 Million EUR | 0.0% |
2007 Q1 | 4.66 Million EUR | 0.0% |
2007 FY | 18.64 Million EUR | 17.81% |
2007 Q4 | 4.64 Million EUR | -0.42% |
2007 Q3 | 4.66 Million EUR | 0.0% |
2006 Q2 | 3.95 Million EUR | 0.0% |
2006 FY | 15.82 Million EUR | 27.2% |
2006 Q1 | 3.95 Million EUR | 0.0% |
2006 Q3 | 3.95 Million EUR | 0.0% |
2006 Q4 | 4.66 Million EUR | 17.8% |
2005 Q4 | 3.95 Million EUR | 27.2% |
2005 FY | 12.44 Million EUR | 0.0% |
2005 Q1 | 3.11 Million EUR | 0.0% |
2005 Q2 | 3.11 Million EUR | 0.0% |
2005 Q3 | 3.11 Million EUR | 0.0% |
2004 Q4 | 3.11 Million EUR | 0.0% |
Name | Net Income | Net Income Difference |
---|---|---|
Boiron SA | 35.82 Million EUR | -55.079% |
Laboratorios Farmaceuticos Rovi, S.A. | 170.33 Million EUR | 67.382% |
Valneva SE | -101.42 Million EUR | 154.777% |
AB Science S.A. | -10.04 Million EUR | 652.946% |
Nanobiotix S.A. | -39.7 Million EUR | 239.95% |
PHAXIAM Therapeutics S.A. | -23.48 Million EUR | 336.546% |
Vivoryon Therapeutics N.V. | -28.34 Million EUR | 296.034% |
BioSenic S.A. | -28.77 Million EUR | 293.064% |
ABIVAX Société Anonyme | -147.74 Million EUR | 137.607% |
Formycon AG | 75.79 Million EUR | 26.697% |